Relationship of serum uric acid and Killip class on mortality after acute ST-segment elevation myocardial infarction and primary percutaneous coronary intervention

International Journal of Cardiology

Volumn 226, Issue , 2017, Pages 26-33

  Liu, Cheng Wei ^a,b,c   Liao, Pen Chih ^a   Chen, Kuo Chin ^a   Chiu, Yu Wei ^a,d   Liu, Yuan Hung ^a   Ke, Shin Rong ^a   Wu, Yen Wen ^a,e,f  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d YUAN ZE UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Inflammation; Killip class; Myocardial infarction; Percutaneous coronary intervention; Serum uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; BIOLOGICAL MARKER;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INTRAAORTIC BALLOON PUMP; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; URIC ACID BLOOD LEVEL; BLOOD; CLASSIFICATION; MIDDLE AGED; MORTALITY; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRENDS;

AGED; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; URIC ACID;

EID: 84992436583     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.10.025     Document Type: Article

References (36)

1. [1] Ruggiero, C., Cherubini, A., Ble, A., Bos, A.J.G., Maggio, M., Dixit, V.D., et al. Uric acid and inflammatory markers. Eur. Heart J. 27 (2006), 1174–1181.
2. [2] Feig, D.I., Kang, D.-H., Johnson, R.J., Uric acid and cardiovascular risk. N. Engl. J. Med. 359 (2008), 1811–1821.
3. [3] Zhao, G., Huang, L., Song, M., Song, Y., Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231 (2013), 61–68.
4. [4] Odden, M.C., Amadu, A.-R., Smit, E., Lo, L., Peralta, C.A., Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am. J. Kidney Dis. 64 (2014), 550–557.
5. [5] Juraschek, S.P., Tunstall-Pedoe, H., Woodward, M., Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish heart health extended cohort study. Atherosclerosis 233 (2014), 623–629.
6. [6] Culleton, B.F., Larson, M.G., Kannel, W.B., Levy, D., Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann. Intern. Med. 131 (1999), 7–13.
7. [7] Wheeler, J.G., Juzwishin, K.D.M., Eiriksdottir, G., Gudnason, V., Danesh, J., Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med., 2, 2005, e76.
8. [8] Kim, S.Y., Guevara, J.P., Kim, K.M., Choi, H.K., Heitjan, D.F., Albert, D.A., Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 62 (2010), 170–180.
9. [9] Trkulja, V., Car, S., On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies. Croat. Med. J. 53 (2012), 162–172.
10. [10] Lazzeri, C., Valente, S., Chiostri, M., Sori, A., Bernardo, P., Gensini, G.F., Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers. Int. J. Cardiol. 138 (2010), 206–209.
11. [11] Akpek, M., Kaya, M.G., Uyarel, H., Yarlioglues, M., Kalay, N., Gunebakmaz, O., et al. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. Atherosclerosis 219 (2011), 334–341.
12. [12] Kaya, M.G., Uyarel, H., Akpek, M., Kalay, N., Ergelen, M., Ayhan, E., et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am. J. Cardiol. 109 (2012), 486–491.
13. [13] Omidvar, B., Ayatollahi, F., Alasti, M., The prognostic role of serum uric acid level in patients with acute ST elevation myocardial infarction. J. Saudi Heart Assoc. 24 (2012), 73–78.
14. [14] Ozgur Akgul, H.U., Pusuroglu, H., Gul, M., Isiksacan, N., Turen, S., Erturk, M., Surgit, O., Cetin, M., Bulut, U., Baycan, O.F., Uslu, N., Predictive value of elevated uric acid in Turkish patients undergoing primary angioplasty for ST elevation myocardial infarction. Acta Cardiol. Sin. 30 (2014), 119–127.
15. [15] von Lueder, T.G., Girerd, N., Atar, D., Agewall, S., Lamiral, Z., Kanbay, M., et al. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the high-risk myocardial infarction database initiative. Eur. J. Heart Fail. 17 (2015), 1144–1151.
16. [16] Chiara Lazzeria, S.V., Chiostria, M., Gensinia, G.F., Long-term prognostic role of uric acid in patients with ST-elevation myocardial infarction and renal dysfunction. J. Cardiovasc. Med. 16 (2015), 790–794.
17. [17] Lazzeri, C., Valente, S., Chiostri, M., Picariello, C., Gensini, G., Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern. Emerg. Med. 7 (2012), 33–39.
18. [18] Baumann, S., Huseynov, A., Koepp, J., Jabbour, C., Behnes, M., Becher, T., et al. Comparison of serum uric acid, bilirubin, and C-reactive protein as prognostic biomarkers of in-hospital MACE between women and men with ST-segment elevation myocardial infarction. Angiology, 2015.
19. [19] Lazzeri, C., Valente, S., Chiostri, M., Spini, V., Angelotti, P., Gensini, G.F., Uric acid and mild renal impairment in patients with ST-elevation myocardial infarction. Scand. Cardiovasc. J. 49 (2015), 14–19.
20. [20] Kumbhani, D.J., Cannon, C.P., Fonarow, G.C., Liang, L., Askari, A.T., Peacock, W.F., et al. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA 302 (2009), 2207–2213.
21. [21] Cheng-Wei Liu, P.-C.L., Chen, K.-C., Hsu, J.-C., Li, A.-H., Tu, C.-M., Wu, Y.-W., Baseline hemoglobin levels associated with one-year mortality in ST-segment elevation myocardial infarction patients. Acta Cardiol. Sin., 2016 (in-press).
22. [22] Yi-Heng Li, H.-I.Y., Tsai, C.-T., Liu, P.-Y., Lin, T.-H., Wu, T.-C., Hung, K.-C., Hsieh, Y.-C., Mar, G.-Y., Fang, C.-Y., Chiu, K.-M., Cheng, J.-J., Chen, J.-H., 2012 guidelines of the Taiwan Society of Cardiology (TSOC) for the management of ST-segment elevation myocardial infarction. Acta Cardiol. Sin. 28 (2012), 63–89.
23. [23] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E., Chung, M.K., de Lemos, J.A., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial InfarctionA report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 61 (2013), e78–e140.
24. [24] Morrow, D.A., Antman, E.M., Charlesworth, A., Cairns, R., Murphy, S.A., de Lemos, J.A., et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of Infarcting myocardium early II trial Substudy. Circulation 102 (2000), 2031–2037.
25. [25] Kojima, S., Sakamoto, T., Ishihara, M., Kimura, K., Miyazaki, S., Yamagishi, M., et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese acute coronary syndrome study). Am. J. Cardiol. 96 (2005), 489–495.
26. [26] De Gennaro, L.B.N., Montrone, D., De Rosa, F., Cuculo, A., Di Biase, M., Subacute inflammatory activation in subjects with acute coronary syndrome and left ventricular dysfunction. Inflammation 35 (2012), 363–370.
27. [27] Lee, S.H., Kim, J.H., Jeong, M.H., Park, H., Jeong, Y.A., Ahn, Y., et al. Clinical characteristics and outcomes of acute ST-segment elevation myocardial infarction in younger Korean adults. Korean Circ. J. 45 (2015), 275–284.
28. [28] Ma, W., Liang, Y., Zhu, J., Yang, Y., Tan, H., Yu, L., et al. Impact of admission systolic blood pressure and antecedent hypertension on short-term outcomes after ST-segment elevation myocardial infarction: strobe-compliant article. Medicine, 94, 2015, e1446.
29. [29] Shiomi, H., Nakagawa, Y., Morimoto, T., Furukawa, Y., Nakano, A., Shirai, S., et al. Association of onset to balloon and door to balloon time with long term clinical outcome in patients with ST elevation acute myocardial infarction having primary percutaneous coronary intervention: observational study. BMJ (Clinical research ed), 344, 2012, e3257.
30. [30] Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H., et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur. J. Heart Fail. 16 (2014), 15–24.
31. [31] Malek, F., Ostadal, P., Parenica, J., Jarkovsky, J., Vitovec, J., Widimsky, P., et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the acute HEart FAilure database registry. J. Crit. Care 27:737 (2012), e11–e24.
32. [32] Wijnands, J.M.A., Boonen, A., Dagnelie, P.C., van Greevenbroek, M.M.J., van der Kallen, C.J.H., Ferreira, I., et al. The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. Rheumatology 53 (2014), 2053–2062.
33. [33] Krishna, M., Zacharowski, K., Principles of intra-aortic balloon pump counterpulsation. Contin. Educ. Anaesth. Crit. Care Pain 9 (2009), 24–28.
34. [34] Chen, C.C., Hsu, Y.J., Lee, T.M., Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H1107–H1117.
35. [35] Nozari, Y., Geraiely, B., Correlation between the serum levels of uric acid and HS-CRP with the occurrence of early systolic failure of left ventricle following acute myocardial infarction. Acta Med. Iran. 49 (2011), 531–535.
36. [36] Higgins, P., Dawson, J., Lees, K.R., McArthur, K., Quinn, T.J., Walters, M.R., Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 30 (2012), 217–226.